Top Story Today
Trump Cuts the Childhood Vaccine Schedule to 11 Shots, and the Fallout Is Just Beginning
An executive order signed August 10 reclassifies several childhood vaccines, including hepatitis B, rotavirus, and flu, from universally recommended to shared clinical decision-making categories. That's a political override of a process scientists have controlled for decades. Merck faces an estimated $2 billion annual revenue hit, and pediatricians are calling it reckless. States still set their own mandates, so nothing changes overnight. But when federal recommendations shift, insurance coverage gets murkier, parents get confused, and vaccination rates drift. The legal footing is shaky too: courts have already blocked earlier schedule changes made without the usual advisory committee process.
Why it matters: This transforms vaccine policy from a science-driven process into a political football that changes with administrations, injecting years of uncertainty into revenue models for every major vaccine manufacturer.
Read more →Regulatory Moves
The FDA Just Created a Pathway to Approve a Drug for One Patient
A new FDA framework lets developers prove a gene therapy should work based on biology rather than massive clinical trials, opening the door for treatments targeting ultra-rare diseases that affect only a handful of people. Researchers already delivered a custom CRISPR therapy to an infant in six months using similar principles. Ultragenyx, Solid Biosciences, and Beam Therapeutics are well positioned, but the trillion-dollar question remains: who pays for a drug built for one person?
Read more →ITM's Cancer Drug Aced Its Trial but Got Rejected Anyway
ITM Isotope's radiopharmaceutical delivered nearly 10 extra months of progression-free survival in a Phase 3 trial, then got rejected by the FDA over manufacturing problems. The clinical data wasn't the issue; the production line was. Novartis's competing Lutathera gets breathing room, and the whole radiopharma sector gets a reminder that factory readiness matters as much as efficacy.
Read more →China Keeps Approving This Two-in-One Cancer Drug
Akeso's ivonescimab, a bispecific antibody that hits PD-1 and VEGF simultaneously, scored its third Chinese lung cancer approval in two years. In one trial, it nearly doubled progression-free survival versus Keytruda. Summit Therapeutics holds U.S. rights and faces an FDA decision in November, setting up what could be Keytruda's first real competitive test.
Read more →Deals and M&A
The Biggest Radiopharmaceutical Deal Ever Just Landed
Curium agreed to buy Lantheus for up to $8 billion, creating a vertically integrated nuclear medicine giant spanning isotope production, drug manufacturing, and therapeutic delivery. The 38% premium over Lantheus's 60-day average wasn't enough to wow Wall Street; shares barely budged. Analysts flagged potential antitrust scrutiny, and roughly $1.3 billion of the price tag is tied to commercial milestones through 2030.
Read more →Jazz Bets $1.3 Billion on a Disease Affecting 3,000 People
Jazz Pharmaceuticals is acquiring Actio Biosciences and its experimental oral drug for KCNT1 epilepsy, a devastating childhood seizure disorder with zero approved treatments. The deal: $820 million upfront, $500 million in milestones. The drug is just entering patient trials, so Jazz is buying early and banking on its Epidiolex-era relationships with pediatric neurologists to build a precision epilepsy franchise.
Read more →Zydus Quietly Expands Its Rare Disease Shopping Spree
Zydus subsidiary Sentynl signed an option-and-license deal for alvelestat, an oral drug targeting a genetic lung disease called Alpha-1 antitrypsin deficiency. The deal includes a non-refundable option fee plus up to $40 million in upfront and R&D payments after option exercise, along with double-digit tiered royalties. It's the latest in a string of rare disease pickups by the Indian pharma group, which has been snapping up orphan assets too small for big pharma to chase. Phase 3 starts in early 2027.
Read more →Clinical Trials and Pipeline
An LSD-Derived Pill Just Aced Its Second Phase 3 in Anxiety
Definium Therapeutics posted a second consecutive Phase 3 win with DT120, a single-dose LSD-derived tablet for generalized anxiety disorder. Patients improved by 5.4 points over placebo on the gold-standard anxiety scale, roughly double what most SSRIs achieve. One dose, twelve weeks of benefit, no serious adverse events. A third confirmatory trial reads out in September.
Read more →Vertex's CF Monopoly Just Got Safer
Sionna Therapeutics' cystic fibrosis drug missed its primary endpoint by a mile, managing just a 1.0 mmol/L improvement versus placebo when it needed 10. The stock dropped 90% in a single session, Vertex popped 6%, and the company shelved the program. Vertex's Trikafta, which pulled in $10.3 billion last year, keeps its crown unchallenged.
Read more →MoonLake's Silence After 'Positive' Trial Results Is Getting Awkward
STAT News is questioning why MoonLake Immunotherapeutics announced "positive" Phase 3 results for its psoriatic arthritis drug without releasing the underlying data investors need to evaluate it. The stock has already fallen roughly 70% in the past year. The drug's nanobody design is genuinely novel, which makes the lack of transparency all the more puzzling.
Read more →Industry Watch
Big Pharma Pledges Half a Trillion Dollars to Build Factories in America
With 100% tariffs on imported patented drugs now in effect, pharma companies have collectively pledged roughly $500 billion in U.S. manufacturing investments. Eli Lilly, AstraZeneca, Roche, and GSK are leading the charge, but analysts warn that building a pharma plant takes three to five years. Domestic production also costs more, so don't expect lower drug prices anytime soon.
Read more →